Results 51 to 60 of about 6,509 (259)

Over the edge: Empirical evidence for the cliff‐edge model of obstetric selection

The Anatomical Record, EarlyView.
Abstract The cliff‐edge model of obstetric selection maintains that larger neonates and smaller birth canals confer a positive selective advantage until labor becomes obstructed and vaginal delivery is no longer possible, eliciting an abrupt reduction in fitness.
Laura M. Watson, Pierre Frémondière, Kaspar Staub, Philipp Mitteroecker, Barbara Fischer, Martin Haeusler, Nicole M. Webb   +6 more
wiley   +1 more source

Osimertinib-related myotoxicity: a disproportionality analysis of the FDA adverse event reporting system

BMC Cancer
Background Osimertinib is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor that has been widely applied as a standard first-line treatment in advanced non-small cell lung cancer.
Yaqian Tan, Qi Song
doaj   +1 more source

Twin pregnancies and the limits of the energetics of gestation and growth hypothesis

The Anatomical Record, EarlyView.
Abstract The “Energetics of Gestation and Growth” (EGG) hypothesis proposes that human birth timing and the associated secondary altriciality of human newborns is determined by limits in maternal metabolic capacity. According to this model, labor is triggered when the increasing fetal energy requirements exceed the expectant mother's maximum sustained ...
Cédric Cordey, Nicole M. Webb, Martin Haeusler   +2 more
wiley   +1 more source

Comparative risk of Guillain–Barré syndrome recombinant and live zoster vaccines: a pharmacovigilance study using VAERS and EudraVigilance database

Immunological Medicine
This study aimed to compare the risk signals of Guillain–Barré syndrome (GBS) associated with recombinant zoster vaccine (RZV) and zoster vaccine live (ZVL) to improve understanding of herpes zoster vaccine safety.
Yinpeng Xu, Fang Li, Li Huang, Dan Mei, Pengqiang Du   +4 more
doaj   +1 more source

Safety of Inclisiran: A Disproportionality Analysis from the EudraVigilance Database

Pharmaceuticals
Introduction: The discovery of serine protease proprotein convertase subtilisin-kexin type 9 (PCSK9) has revolutionized pharmacological lipid-lowering treatments. The first PCSK9 antagonists (PCSK9-A), evolocumab and alirocumab, were approved in 2015.
Giuseppe Cicala, Michelangelo Rottura, Viviana Maria Gianguzzo, Federica Cristiano, Selene Francesca Anna Drago, Giovanni Pallio, Natasha Irrera, Egidio Imbalzano, Edoardo Spina, Vincenzo Arcoraci   +9 more
openaire   +4 more sources

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

British Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun, Jingrong Yang, Lei Wan, Xia Xu, Jing Wang   +4 more
wiley   +1 more source

Drug-induced movement disorder: A disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2004 to 2024.

PLoS ONE
BackgroundAlthough many drugs have been associated with drug-induced movement disorders (DIMDs), the associated risks are unclear. This study aimed to identify high-risk drugs for DIMDs through disproportionality analysis of the Food and Drug ...
Jingjing Zou, Chenju Zhan, Yan Feng, Qixi Liu, Guohao Peng, Zhongjie Cai, Lingling Luo, Jun Zou   +7 more
doaj   +1 more source

Evaluating the (comparative) safety profile of the novel oral polio vaccine type 2 using individual case safety reports in VigiBase

British Journal of Clinical Pharmacology, EarlyView.
Aim Novel oral polio vaccine type 2 (nOPV2) was used under the WHO emergency use listing for circulating vaccine‐derived polio virus (cVDPV) outbreaks from 2021 to 2023. We assessed nOPV2 adverse events following immunization (AEFIs) and compared its safety profile to other vaccines using VigiBase.
Comfort Kunak Ogar, Malede Mequanent Sisay, Leonardo Roque‐Pereira, Christine Leopold, Patrick C. Souverein, Aukje K. Mantel‐Teeuwisse, Marie L. De Bruin   +6 more
wiley   +1 more source

Disproportionality analysis of reslizumab based on the FDA Adverse Event Reporting System

Therapeutic Advances in Drug Safety
Background: With the increasing prescription of reslizumab for severe asthma with an eosinophilic phenotype, a real-world pharmacovigilance analysis of reslizumab is urgently required to detect potential unreported adverse events (AEs) in clinical ...
Huqun Li, Cuilian Guo, Chongshu Wang
doaj   +1 more source

Case‐malformed signal detection and prioritisation using EUROmediCAT data for pharmacovigilance in pregnancy

British Journal of Clinical Pharmacology, EarlyView.
Aim Many women take medications during pregnancy. However, the risk to the fetus from most medications is uncertain. Congenital anomalies are one of the leading causes of infant death and contribute to long‐term disability. Signal detection methods can be used to systematically identify possible medication–anomaly associations that require further ...
Hannah Johnson, Helen Dolk, Maria Loane, Christine Damase‐Michel, Joanne Given, Hedvig Nordeng, Jorieke E. H. Bergman, Iain Carey, Elly Den Hond, Ester Garne, Florence Rouget, Lea Bruneau, Isabelle Monier, Anke Rissmann, Mary O'Mahony, Miriam Gatt, Renée Lutke, Joanna Sichitiu, Elisa Ballardini, Alessio Coi, Clara Cavero Carbonell, David Tucker, Joan Morris   +22 more
wiley   +1 more source